Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6777
IPSCIO Record ID: 6823
IPSCIO Record ID: 237254
Pursuant to the Unilateral Development and Commercialization agreement, Licensor grants with respect to each Unilateral Product, an exclusive, even as to Licensor and its Affiliates, worldwide right and license, with the right to sublicense, under the Licensor Technology, the Collaboration Technology and the Joint Technology to Exploit such Unilateral Products in the Territory.
The Collaboration is for the jointly research, develop and commercialize human antibodies against Licensee cancer targets.
IPSCIO Record ID: 28868
(a) make or have made Licensed Antibody Phage Display Materials;
(b) solely for Research and Development purposes, conduct Antibody Phage Display;
(c) make or have made Research Quantities of a Licensed Immunoglobulin;
(d) transfer Antibody Phage Display Materials;
(e) transfer Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Company Collaborator or a Development Partner of the Company;
(f) sell, offer to sell, import and export Licensed Immunoglobulins;
(g) use Licensed Immunoglobulins; and
(h) use, offer for sale, sell, import and export Products for use in the treatment, prophylaxis, diagnosis or monitoring of a human disease state or condition.
The Company is willing to grant the Irish Licensor non-exclusive licenses, in order to permit the Irish Licensor to engage in certain research, development and commercial activities.
Licensed antibody phage display materials means any collection or library of polynucleotide sequences which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin or at least a functionally operating region of an antibody variable region and an outer surface polypeptide of a bacteriophage.
IPSCIO Record ID: 1395
(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.
â€œHumanized Antibody(ies)â€ means the humanized form of the Murine Antibody.
â€œLicensed Product(s)â€ means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.
â€œMurine Antibody(ies)â€ means, subject to Section 2.01(b), the murine monoclonal antibody designated as â€œPRO 140â€ directed against the Target Antigen.
IPSCIO Record ID: 222549
For the commercial license, Licensor grant the following licenses, on an Licensee Target-by-Licensee Target basis
– a worldwide, exclusive, non-transferable license, with the right to grant a sublicense to its Affiliates, under the Licensor Technology to immunize the Mice to make Antibodies against such Licensee Target, and
– a worldwide exclusive license under the Licensor Technology, with the right to sublicense, to make, have made, import, have imported, use, offer for sale and sell Products containing Antibodies against such Licensor Target.
Licensee shall have no right to grant sublicenses to use the Mice, but may grant sublicenses under
the Licensee Technology to the extent necessary to develop, make, have made, import, use, offer for
sale and sell Products.
Licensor Technology includes the Confidential Information and Mice, and patent rights which claims an invention which is necessary for the use of the Mice to prepare the Antibodies or to develop, produce, make, have made, import, have imported, use, offer for sale and sell the Antibodies.
The Product shall mean any composition or formulation comprising one or more Antibodies, or a portion thereof, for the diagnosis, prophylaxis or treatment of human disease.
Licensee Target shall mean an Antigen selected by Licensee for immunization of Licensors HuMAb mice to generate human antibodies directed against an Antigen, in each case, which Licensor has informed Licensee is available for licensing.
HuMAb -Mouse technology is a transgenic mouse system that creates high affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.
Incorporating this technology into Licensee's broad drug discovery program will significantly enhance Licensee continuing efforts to identify new drug candidates.
IPSCIO Record ID: 2946
The collaboration includes a grant by the Company to Parent of a worldwide License to commercialize ipilimumab, a fully human antibody product developed using the Companyâ€™s UltiMAbÂ® technology, that is antagonistic to cytotoxic T-lymphocyte antigen 4 (CTLA-4). The collaboration further includes a grant by the Company to Parent of a License to commercialize MDX-1379 subject to the terms of the License granted by the United States Public Health Service to the Company on May 6, 2003. Under the Collaboration Agreement, Parent is required to pay upfront fees, regulatory milestone payments and royalties.
Parent is responsible for 65% of all development costs related to clinical trials intended to support regulatory approval in both the United States and the European Union, with the remaining 35% to be paid by the Company. The parties share equally the costs of any clinical trials of products intended solely for regulatory approval in the United States, and Parent is fully responsible for all development efforts that relate solely to regulatory approval in the European Union and other parts of the world.
IPSCIO Record ID: 7769
IPSCIO Record ID: 233496
During the Research term of this agreement, Licensee shall not make any other grant to the related antigens.
Antigens shall mean, collectively, the Research Antigens, Eligible Antigens, Optioned Antigens and Licensed Antigens, and Antigen shall mean any one of the Antigens.
Research Antigens shall mean, collectively, the antigens which are selected by the Collaboration, Licensor or Licensee for use in the Research Program, for which Licensor and Licensee have the right to grant the other party the commercial license, and which are not Optioned Antigens or Licensed Antigens, and Research Antigen shall mean any one of the Research Antigens.
The Diagnostic Field shall mean the use of Products for the following human medical purposes the detection, diagnosis and monitoring of any disease, predisposition, state or condition in humans or the selection of a particular patient(s) to receive a particular therapeutic treatment(s).
The Therapeutic Field shall mean the use of Products for the following human medical purposes the prevention or treatment of any disease, state or condition in humans.
The goal of the five-year alliance is to develop antibody therapeutics against promising antibody drug targets in the human genome. The candidates are intended to treat a broad range of diseases, including metabolic diseases, cancer, inflammation, and autoimmune disorders.